Group 1 - The company, Zhendong Pharmaceutical, announced that as of July 31, 2025, it has repurchased a total of 12,916,700 shares through a dedicated securities account via centralized bidding, which represents 1.28% of the company's current total share capital [2]

格隆汇8月1日丨振东制药(300158.SZ)公布，截至2025年7月31日，公司累计通过股份回购专用证券账户 以集中竞价交易方式回购公司股份12,916,700股，占公司目前总股本比例为1.28%，回购最高成交价为 人民币5.03元/股，回购最低成交价为人民币3.51元/股，成交总金额为人民币51,025,218元（不含交易费 用）。 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-040 山西振东制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"） 分别于 2024 年 10 月 22 日、11 月 12 日召开公司第六届董事会第二 次会议、2024 年第二次临时股东大会，审议通过了《关于回购公司 股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购 公司部分股份，回购的股份将全部用于注销并减少公司注册资本。本 次用于回购股份的资金总额上限为人民币 10,000 万元，回购下限为 人民币 5,000 万元，回购价格不超过人民币 6.00 元/股（含本数）， 回购股份的实施期限为自公司股东大会审议通过本次回购股份方案 之日起不超过 12 个月。具体内容详见公司于 2024 年 10 月 24 日、2024 年 11 月 12 日刊登在巨潮资讯网（www.cninfo.com.cn）的相关公告。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股 份》等相关规定， ...

证券日报网讯振东制药（300158）7月31日在互动平台回答投资者提问时表示，公司无药品可用于基孔 肯雅热的治疗。 ...

Group 1: Market Performance - Major indices declined on July 31, with the Shanghai Composite Index down 1.18%, Shenzhen Component down 1.73%, ChiNext down 1.66%, and the STAR Market down 1.01%. Over 1,000 stocks rose in the two markets, with a total trading volume of approximately 1.94 trillion yuan [2] - The AI sector showed strong performance, with stocks like Kexin New Energy (300731.SZ) rising 12.82%, and Industrial Fulian (601138.SH) and Youke De (688158.SH) both increasing over 6% [2] Group 2: AI Industry Growth - According to CCID Consulting, China's AI industry is expected to experience explosive growth this year, leading the global market. The industry is projected to grow from 398.5 billion yuan in 2025 to 1,729.5 billion yuan by 2035 [2] Group 3: Assisted Reproductive Technology Stocks - Stocks related to assisted reproduction surged, with Anke Bio (300009.SZ) and Gongtong Pharmaceutical (300966.SZ) both rising 20%, and Guangshengtang (300436.SZ) increasing over 18% [3] - The Ministry of Finance announced a budget of 90 billion yuan for a new "child-rearing subsidy fund" as part of a broader initiative to support fertility policies [3] Group 4: Innovative Pharmaceuticals - Innovative drug stocks also performed well, with Zhendong Pharmaceutical (300158.SZ) rising over 16% and Shutaishen (300204.SZ) increasing over 10% [3] - According to Industrial Securities, China's innovative drug industry is transitioning to a leading position, with significant opportunities expected in 2025 as many products are projected to exceed 3 to 5 billion USD in peak sales [3] Group 5: Declining Sectors - The anti-involution sector saw significant declines, with steel, coal, and photovoltaic sectors being heavily impacted. Stocks like Baogang Co. (600010.SH) and Anyang Steel (600569.SH) fell over 7% [4] - Other sectors such as real estate, securities, liquor, film, and precious metals also showed weakness, with stocks like Happiness Blue Ocean (300528.SZ) dropping over 8% [4]

7月31日，医疗美容概念上涨0.43%，今日主力资金流入2.44亿元，概念股24只上涨，46只下跌。 主力资金净流入居前的分别为安科生物（4.03亿元）、常山药业（2.5亿元）、汉商集团（1.1亿元）、 乐普医疗（6230.96万元）、振东制药（4677.6万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300009安科生物12.1120.024.03亿元10.5%2300255常 山药业42.33.172.50亿元9.44%3600774汉商集团11.3310.01.10亿元40.97%4300003乐普医疗 15.560.846230.96万元5.49%5300158振东制药8.6216.644677.60万元2.15%6300238冠昊生物 17.41.163491.91万元8.34%7300753爱朋医疗31.397.283162.54万元5.27%8000725京东方Ａ4.04- 0.982808.99万元1.6%9000935四川双马19.550.572758.18万元9.8%10300244迪安诊断16.11.582710.14万元 4.4% 来源：金融界 ...

格隆汇7月31日丨振东制药(300158.SZ)在互动平台表示，公司无药品可用于基孔肯雅热病毒的治疗。 ...

格隆汇7月31日丨振东制药(300158.SZ)在互动平台表示，达霏欣牌米诺地尔搽剂用于治疗男性型脱发和 斑秃。 ...

格隆汇7月31日丨振东制药(300158.SZ)在互动平台表示，公司无药品可用于基孔肯雅热病毒的治疗。 ...

Group 1 - The company, Zhendong Pharmaceutical (300158.SZ), announced on the interactive platform that it has developed a mosquito-repellent wristband and a special drug for the prevention and treatment of arboviruses [1]